Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models.
Sonia JainJessica I GriffithKendra A PorathSneha RathiJiayan LeTugce I PasaPaul A DeckerShiv K GuptaZeng HuBrett L CarlsonKatrina K BakkenDanielle M BurgenskeThomas M FeldsienDidier R LefebvreRachael Ann VaubelJeanette E Eckel-PassowEdward B ReillyWilliam F ElmquistJann N SarkariaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
EGFR-targeting ADCs are promising therapeutic options for GBM when delivered intratumorally by CED. However, the linker and payload for the ADC must be carefully considered to maximize the therapeutic window.